ARCB vs CMRE

ArcBest Corporation's Piotroski F-Score of 4/9 indicates weak financial health, signaling deterioration in operational efficiency and profitability. The absence of an Altman Z-Score raises concern about potential distress risk, especially given a current ratio of 0.95 and quick ratio of 0.79, both below safe thresholds. Despite a seemingly attractive forward P/E of 11.68, the company exhibits negative revenue growth (-2.90% YoY) and severe earnings declines (YoY EPS down 72.9%), undermining long-term sustainability. The Graham Number of $58.46 suggests a defensive fair value, yet the stock trades at $84.87—over 44% above this benchmark—indicating significant overvaluation. Analysts' 'buy' recommendation appears misaligned with deteriorating fundamentals.

CMRE presents a classic deep-value profile, trading significantly below its Graham Number ($34.68) and Intrinsic Value ($91.16) with a very low P/E of 5.34. While the Piotroski F-Score of 4/9 indicates stable but mediocre financial health, the company maintains strong profitability margins (41.53%) and a conservative payout ratio. However, the outlook is clouded by a severe decline in quarterly revenue (-61.35% Q/Q) and a highly bearish technical trend (10/100). The disconnect between massive valuation discounts and deteriorating top-line growth suggests a potential value trap.